However, it has been recently shown that approximately 25% of patients with IPF (those carrying the TOLLIP rs3750920 TT genotype) may benefit from NAC therapy, whereas those with the rs3750920 CC genotype may be more susceptible to treatment-related harm [47]. Here, TOLLIP is linked to idiopathic interstitial pneumonia.